You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Baxter
AstraZeneca
McKesson
Moodys

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,125,149


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,125,149 protect, and when does it expire?

Patent 10,125,149 protects ZERBAXA and is included in one NDA.

This patent has four patent family members in three countries.

Summary for Patent: 10,125,149
Title:Synthesis of cephalosporin compounds
Abstract: Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising a palladium-catalyzed coupling reaction. Provided herein are methods for the synthesis of cephalosporin compounds of formula (I) employing a palladium-catalyzed alkylation reaction, as well as compositions related to the same. In an aspect, provided herein is a method for preparing a compound of formula (II), or a salt thereof, comprising the step of admixing, e.g., reacting, a compound of formula (III), or a salt thereof, with a nucleophile (Nuc) in the presence of reagents comprising: (a) a palladium source; and (b) a palladium-binding ligand, to form a compound of formula (II), or a salt thereof.
Inventor(s): Waller; David (Somerville, MA), Gazda; Gregory (Sudbury, MA), Minden; Zachary (Watsonville, CA), Barton; Lisa (Haverhill, MA), Leigh; Clifton (Windham, NH)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:15/503,907
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 10,125,149

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;INTRAVENOUS 206829-001 Dec 19, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,125,149

PCT Information
PCT FiledAugust 14, 2015PCT Application Number:PCT/US2015/045287
PCT Publication Date:February 18, 2016PCT Publication Number: WO2016/025839

International Family Members for US Patent 10,125,149

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 106795175   Start Trial
China 110204558   Start Trial
European Patent Office 3180347   Start Trial
World Intellectual Property Organization (WIPO) 2016025839   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
McKinsey
Moodys
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.